Inclusion Body Myositis
Inclusion Body Myositis (IBM) is a rare muscle disorder that leads to progressive weakness and wasting of the muscles, particularly in the arms and legs, often affecting older adults.
Inclusion Body Myositis: ABC008 Treatment Study
We are studying the safety and effectiveness of a new treatment called ABC008 for people with Inclusion Body Myositis. The goal is to see if it improves muscle function and strength compared to a placebo.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you over 40 years old?
- Do you have a diagnosis of inclusion body myositis (IBM)?
- Are you currently pregnant or breastfeeding?
- Are you taking any medications like prednisone (more than 7.5 mg/day), cyclosporine, or methotrexate?
- Have you had any other form of myositis or myopathy, like polymyositis or muscular dystrophy?
What similar medicines might you know?
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Acidwell
Acipan
Acipan Control
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Az Sint-Lucas & Volkskliniek
Neurology
Gent, Belgium
Assistance Publique Hopitaux De Paris
Médecine interne
Salpêtrière, France
Universitaetsklinikum Duesseldorf AöR
Klinik für Neurologie
Düsseldorf, Germany
Sponsor: Abcuro Inc.
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.